Correspondance with management thread

Hello there fellow holders,

Thought I would start a thread that we can use just for correspondence with management. Matt S and I have posted a few things over the last few months, but might be nice to have those in one place. 

Below is an email response I got from Richard Hopkins this morning, and attached is a Q & A I did with Harry Karelis a few months pack (previously posted in this forum).

I hope you all find this useful 

All the best


Hi Harry, 

Great to hear from you again and thanks for your continued interest in Zelda.

I wanted to clarify with you whether or not Zelda will be pursuing and announcing a new area of research in 2018. There have been references to this in previous announcements, and in my exchanges a few months back with Harry Karelis, he mentioned that the paperwork for a new research area was being finalised with the institution involved.

Is this still being pursued and will be announced this year?

Yes, we’re continuing to progress opportunities relating to new areas of research/clinical studies. We’re also working very closely with our medical advisory board, including the 2 recent appointments Dr Dustin Sulak and Dr David Casarett, to help optimise the protocols and to ensure they are world class.  Their insights have been invaluable. 

We’re still aiming to announce a new initiative this year. 

It has been a shame to see the share price find new 12-month lows these past several weeks, but I'm sure that come June 2019 when results for the insomnia trials are in, things will turn around. If commercialisation follows quite soon after positive results, 2019 could be a very good year for Zelda

While we share your frustrations with the share price, we remain focussed on the business and delivering on what we’d said we'd do.  If the Autism and Insomnia trials yield positive results, we’ll be ready to rapidly commercialise the outcomes.  If we continue to unlock value then the share price should follow.

Best regards

Richard

Correspondence with Harry Karelis - July 2018.pdf